Get the Stockscreener App
1.53
0.66%
0.01
After Hours:
1.58
0.05
+3.27%
Compugen Ltd stock is traded at $1.53, with a volume of 322.97K.
It is up +0.66% in the last 24 hours and up +6.99% over the past month.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
See More
Previous Close:
$1.52
Open:
$1.53
24h Volume:
322.97K
Relative Volume:
1.03
Market Cap:
$136.99M
Revenue:
-
Net Income/Loss:
$1.60M
P/E Ratio:
-3.825
EPS:
-0.4
Net Cash Flow:
$-62.91M
1W Performance:
-4.97%
1M Performance:
+6.99%
6M Performance:
-17.74%
1Y Performance:
-17.30%
1-Day Range:
$1.50
$1.59
1-Week Range:
$1.44
$1.62
52-Week Range:
$1.35
$3.0301
Compugen Ltd Stock (CGEN) Company Profile
Compare CGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
1.53 | 136.99M | 0 | 1.60M | -62.91M | 0.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-22 | Downgrade | Jefferies | Buy → Hold |
| May-26-20 | Resumed | JMP Securities | Mkt Outperform |
| May-13-20 | Initiated | Stifel | Buy |
| May-07-20 | Initiated | SVB Leerink | Outperform |
| Apr-22-20 | Initiated | ROTH Capital | Buy |
| Mar-24-20 | Initiated | SunTrust | Buy |
| Jan-16-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-29-18 | Initiated | Oppenheimer | Outperform |
| Feb-01-16 | Resumed | Oppenheimer | Outperform |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Apr-23-15 | Resumed | Jefferies | Buy |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Feb-07-14 | Initiated | MLV & Co | Buy |
| Dec-28-09 | Reiterated | Cantor Fitzgerald | Buy |
| Jul-29-09 | Initiated | Cantor Fitzgerald | Buy |
View All
Compugen Ltd Stock (CGEN) Latest News
Astrazeneca Plc ADR (AZN-Q) QuotePress Release - The Globe and Mail
Gilead Sciences Inc (GILD-Q) QuotePress Release - The Globe and Mail
Compugen (CGEN) Stock Surges Amid Biotech Industry Movement - GuruFocus.com
Connor Clark & Lunn Investment Management Ltd. Grows Position in Compugen Ltd. (NASDAQ:CGEN) - Defense World
Compugen Bolsters Cancer Therapy Portfolio with New Patent - TipRanks
Compugen Secures Key Patent for Triple Combination Cancer Immunotherapy Through 2037 | CGEN Stock News - StockTitan
Compugen Ltd. (NASDAQ:CGEN) Holdings Raised by Oppenheimer & Co. Inc. - Defense World
Compugen (CGEN) Stock Dips Amidst Biotech Sector Movements - GuruFocus.com
Compugen Ltd. (NASDAQ:CGEN) Short Interest Down 18.1% in October - MarketBeat
Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - Yahoo Finance
Compugen (CGEN) Stock Declines Amidst Industry Downtrend - GuruFocus.com
Compugen Ltd. (NASDAQ:CGEN) Q3 2024 Earnings Call Transcript - Insider Monkey
Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ... - Yahoo Finance
Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ... By GuruFocus - Investing.com Canada
Compugen Reports Strong Q3 2024 Results and Progress - TipRanks
Compugen: Q3 Earnings Snapshot - The Washington Post
Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates - Yahoo Canada Finance
Compugen earnings beat by $0.11, revenue topped estimates - Investing.com India
Compugen Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Compugen to Participate in Stifel 2024 Healthcare Conference - StockTitan
Compugen (CGEN) to Release Quarterly Earnings on Tuesday - Defense World
Compugen (NASDAQ:CGEN) shareholder returns have been stellar, earning 204% in 1 year - Simply Wall St
Compugen Showcases Promising Data on Ovarian Cancer Therapy - TipRanks
Compugen's Cancer Drug Combo Shows 17.4% Response Rate in Ovarian Cancer Trial | CGEN Stock News - StockTitan
Short Interest in Compugen Ltd. (NASDAQ:CGEN) Decreases By 17.1% - MarketBeat
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - cnhinews.com
Compugen Gears Up to Report Q3 Earnings: Here's What to Expect - Yahoo Finance
Compugen to Present New Clinical Data at SITC 2024 - StockTitan
Compugen Ltd. (NASDAQ:CGEN) Shares Sold by Renaissance Technologies LLC - Defense World
Compugen’s stock rockets on deal with Gilead for anti-tumor drug - MSN
Compugen Ltd. (NASDAQ:CGEN) Sees Large Growth in Short Interest - Defense World
CompoSecure Inc (CMPO) Analyst Thoughts: How High Can It Go? - Stocks Register
Compugen Ltd. (NASDAQ:CGEN) Short Interest Update - Defense World
Compugen Shareholders Approve All Proposals - TipRanks
Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Compugen to Present at Single Cell Genomics 2024 Conference - StockTitan
Compugen Ltd (CGEN)’s Market Momentum: Closing Strong at 1.82, Down -7.61 - The Dwinnex
Compugen Ltd’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
Compugen Ltd (CGEN) shows promising results - US Post News
Rothschild Investment LLC Buys Shares of 221,900 Compugen Ltd. (NASDAQ:CGEN) - Defense World
Compugen Ltd Stock (CGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):